2007

Serological cross-reactivity—HLA-A locus

1 CREG
36 1 3 11 30 31

80 29

210
23 203 26 43

2 69 66

19
24 68 34 33 Strong cross-reactivity
28 Cross-reactivity

n Broad specificity
2403 25 32 74
9 CREG (cross-reactive group)

10
B57 B58 17
Inter-locus
cross-reactivity

2 CREG

Prepared by Glenn Rodey, MD, De Novo, Inc., Durango, CO USA

 2007

Serological cross-reactivity—HLA-B locus

7 CREG
48
12 CREG
41 61 4005
40 82 45 50
5 CREG
37 13 60
46 57 58 17 83 44 49
12 21
76 62 63 47

70 15 81
27 7
71 72 75 77 64 703
59
2708 73
35 53 18 65 8 42
14 55 22
78 51 52 5
3901 39 67 56 54 Strong cross-reactivity
3902
5103 5102 Cross-reactivity
16
38 n Broad specificity

CREG (cross-reactive group)

8 CREG

Prepared by Glenn Rodey, MD, De Novo, Inc., Durango, CO USA

2007

Serological cross-reactivity—HLA-Cw locus

B46
Cw6 CREG
Cw3 CREG Cw2 CREG
9 10 17 Cw16
Cw3 7
2 1602 1601 Cw with poorly
defined serological
Cw8 CREG reactivity
6 12
0801/3 0802 5
Cw8 15

1 14 4 18

Cw4 CREG
Strong cross-reactivity

Cross-reactivity

n Broad specificity

CREG (cross-reactive group)

Prepared by Mike Bunce, PhD, Invitrogen Corporation

2007
Serological public epitopes of HLA-A and HLA-B molecules
CREG Found on Public epitopes Possible location
1C A1, 3, 9 (23, 24), 11, 29, 3-4, poorly defined Unclear
30, 31, 36, 80

10C A10 (25, 26, 34, 66),11, 10, 28, 33 (10p) RNTRN 62–66
28 (68, 69), 32, 33, 43, 74

2C 2, 9 (23, 24), 28 (68, 69), 2, 28, 9 (9p) 127 K Example of public epitope locations:
B17 (57, 58) 2, 28 (28p) TTKH 142–145 Public epitopes of the A2 molecules
2, 17 (17p) GETRK 62–66

5C B5 (51, 52), 15 (62, 63,75, 5, 35, 53, 18, 70 (5p) ASPRT 41–45 A2
76, 77, 78), 18, 21 (49, 50), 5, 15, 17, 21, 35, 70, 4005 (21p)
35, 46, 53, 70 (71, 72), 73, 17p
4005, B17 (57, 58) (2, 17)

7C B7, 8, 13, 22 (54, 55, 56), 7, 27, 42, 46, 47, 54, 55, 56 (22p) YKAQA 67–71
27, 40 (60, 61), 41, 42, 47, 7, 13, 27, 60, 61, 47 (27p) E 163
48, 59, 67, 73, 81, 82 7, 8, 41, 42, 48, 60, 81 (7p) DKLE 177–180
7, 60, 4005, 48 (40p) K178

8C 8, 14 (64, 65), 16 (38, 39), 8, 14, 16, 18, 51, 59, 67 (8p) Unclear
18, 51, 59, 67
28p
12C 12 (44, 45), 13, 21 (49, 50), 37, 12, 13, 21, 37, 40, 41, 47 (12p) TSPRK 41–45 (2, 28)
40 (60, 61), 41, 47, 4005, 48, 82

4C B5 (51, 52, 5102, 5103), 0802, Bw4 TLAR or NLAR 80–83

9p
0803, 13, 17 (57, 58), 1809, 27,
37, 38 (16), 44 (12), 47, 49 (21), (2, 28, 9)
53, 5607, 59, 63, 67, 77,
and A23, 24, 25, 32

6C 7, 703, 8, 1309, 18, 2708, 2712, Bw6 NLRG 80–83

2718, 35, 39 (16), 3901, 3902,
4005, 4406, 4409, 45 (12), 46*,
4702, 48, 50 (21), 54 (22),
55 (22), 56 (22), 60 (40), 61 (40),
62 (15), 64 (14), 65 (14), 67,
71 (70), 72 (70), 73, 75 (15),
76 (15), 78, 81
*but does not react with Bw6 antisera Note: 1806, 4601, 5503, and 7301 are negative for both Bw4 and Bw6

Prepared by Glenn Rodey, MD, De Novo, Inc., Durango, CO USA

 2007

HLA-DRB associations
HLA-DRB1 HLA-DRB3, 4, 5
specificities specificities

DR1, 10 DRB1 DRB6 DRB9 None

DR15, 16 (2)
DRB1 DRB6 DRB5 DRB9 DR51
DR1 (uncommon)

DR17, 18 (3)
DR11, 12 (5) DRB1 DRB2 DRB3 DRB9 DR52
DR13, 14 (6)

DR4, 7, 9 DRB1 DRB7 DRB8 DRB4 DRB9 DR53

DR8 DRB1 DRB9 None

The diagrams above represent DNA segments from DRB1 through the DRB9 pseudogene. Each haplotype possesses only one DRB3, 4, or
5 locus. However, DR1, 8, and 10 are lacking these loci, and therefore do not express any DRB3, 4, or 5 alleles.

White boxes indicate nonexpressed pseudogenes. Gray boxes represent expressed genes.

Prepared by Glenn Rodey, MD, De Novo, Inc., Durango, CO USA

www.invitrogen.com

©2007 Invitrogen Corporation. All rights reserved. O-073707-r1 0907